Anti-inflammatory Dietary Intervention in Overweight and Obese Adolescents
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01665742 |
Recruitment Status :
Completed
First Posted : August 15, 2012
Last Update Posted : December 9, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Overweight Obesity | Dietary Supplement: Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopene Dietary Supplement: Placebo supplement | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 58 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Novel Anti-inflammatory Dietary Intervention to Improve the Metabolic Phenotype of Overweight and Obese 13-18 Year Old Adolescents - Insights Into Potential Genetic Susceptibility |
Study Start Date : | January 2012 |
Actual Primary Completion Date : | November 2013 |
Actual Study Completion Date : | November 2013 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Anti-inflammatory supplement
8-weeks of daily supplementation with: 1 x fruit juice fortified with fish oil, and 4 x film-coated tablets containing vitamin C, alpha-tocopherol, green tea extract and lycopene in conjunction with a weight management programme |
Dietary Supplement: Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopene
1 x fruit juice fortified with salmon oil containing 1000mg EPA and 1000mg DHA daily for 8 weeks AND 4 x film-coated tablets containing 561mg vitamin C, 389mg alpha-tocopherol, 416mg green tea extract and 15mg lycopene daily for 8 weeks in conjunction with a weight management programme |
Placebo Comparator: Placebo supplement
8 weeks of daily supplementation with: 1 x fruit juice fortified with high-oleic sunflower oil, and 4 x film-coated placebo tablets in conjunction with a weight management programme |
Dietary Supplement: Placebo supplement
1 x fruit juice fortified fortified with high oleic sunflower oil daily for 8 weeks AND 4 x film-coated placebo tablets daily for 8 weeks in conjunction with a weight management programme |
- Homeostasis model of assessment - insulin resistance [ Time Frame: 8 weeks ]Homeostasis model of assessment - insulin resistance (HOMA-IR) will be derived from fasting glucose and insulin concentrations [(fasting plasma glucose x fasting serum insulin)/22.5] as determined by Matthews et al., 1985
- Adiponectin [ Time Frame: 8 weeks ]Adiponectin, a marker of insulin sensitivity, will be determined pre- and post-intervention.
- Markers of inflammation [ Time Frame: 8 weeks ]Markers of inflammation such as C reactive protein, interleukin (IL) - 6, IL-1β, tumour necrosis factor alpha, intra-cellular adhesion molecule-1, vascular cell adhesion molecule-1, retinol binding protein 4, fibrinogen, white blood cells and related inflammatory markers
- Lipid Profile [ Time Frame: 8 weeks ]Full lipid profile and lipidomic analyses (total triacylglycerol, non-esterified fatty acids, total cholesterol, LDL cholesterol, HDL cholesterol and plasma fatty acid composition, diglycerides, cholesterol esters and sphingomyelins,) and related lipid markers
- Inflammatory genetic variants [ Time Frame: 8 weeks ]Inflammatory genetic variants such as complement component 3, lymphotoxin- α, IL-6, IL-1β, TNF-α, adiponectin polymorphisms and related variants that link to the inflammatory phenotype
- Functional molecular analysis (ex-vivo) [ Time Frame: 8 weeks ]Functional molecular analysis will be conducted to determine which insulin sensitising pathways have been modulated by the intervention

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 13 Years to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female
- 13-18 years
- Body mass index ≥ 91st percentile on UK growth reference charts (Cole, 1995)
- Medications/dietary supplements which do not interfere with the intervention are allowed, on condition that the participants adhere to the same regimen during the intervention, including oral contraceptives and other non-fatty acid based dietary supplements (e.g. garlic)
- Smoker or non-smoker
- Not participating in any other intervention study
Exclusion Criteria:
- Pregnancy or lactation
- Endocrine disorders such as Polycystic Ovary Syndrome
- Currently on treatment for a chronic inflammatory condition such as asthma
- Kidney or liver dysfunction
- Iron deficiency anaemia
- Prescribed anti-inflammatory medication
- Consumers of fatty acid supplements including fish oils, evening primrose oil and antioxidant vitamin (A, C, E, -carotene) supplements
- High consumers of oily fish (> 2 servings/week)
- Participants planning to start a special diet or lose weight (e.g. Slimfast, Atkins etc)
- Weight change ≥3kg within the last 3 months
- Alcohol or drug abuse (based on clinical judgement)
- Participants with an allergy to fish and/or shellfish

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01665742
Ireland | |
Trinity Centre for Health Sciences, St, James's Hospital | |
Dublin 8, Ireland | |
Adelaide and Meath Hospital, Incorporating the National Children's Hospital Dublin, | |
Dublin, Ireland | |
University College Dublin | |
Dublin, Ireland |
Principal Investigator: | Helen M Roche, BSc, MSc, PhD | University College Dublin | |
Principal Investigator: | Fiona Lithander, BSc, PhD | University of Dublin, Trinity College |
Responsible Party: | Prof Helen M Roche, Associate Professor of Nutrigenomics, University College Dublin |
ClinicalTrials.gov Identifier: | NCT01665742 |
Other Study ID Numbers: |
TNS-5 |
First Posted: | August 15, 2012 Key Record Dates |
Last Update Posted: | December 9, 2014 |
Last Verified: | December 2014 |
Obesity Chronic inflammation Anti-inflammatory dietary intervention Genetic susceptibility |
Overweight Overnutrition Nutrition Disorders Body Weight Tocopherols Vitamin E alpha-Tocopherol Lycopene Vitamins |
Micronutrients Physiological Effects of Drugs Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Anti-Inflammatory Agents Radiation-Protective Agents Anticarcinogenic Agents Antineoplastic Agents |